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Background. Dry eye disease (DED) is one of the most common complications following refractive surgery. Purpose. Evaluate the
efficacy of an osmoprotective eye drop (Optive®) for the management of induced DED in refractive surgery patients. Design.
Double-masked randomised controlled trial. Methods. Twenty-two refractive surgery patients oriented to apply FreshTears (FT;
n = 13) or Optive (Op; n = 9), topically, QID, for 3 months. Eye exams were performed before surgery (T0) and 1-month (T1)
and 3-month (T3) follow-up and consisted of tear film osmolarity, Schirmer 1 test, tear film breakup time (TBUT), fluorescein
staining, and ocular surface disease index (OSDI) and patient symptoms questionnaires. Main Outcome Measures. Pain and
osmolarity. Results. Pain increased significantly for FT at T3 (p < 0 05). A reduction in osmolarity was observed at T1 and T3
for Op group (p < 0 01) and at T3 for FT group (p < 0 05). TBUT showed a decrease between T0 and T1 for FT (p < 0 05).
Schirmer 1 values increased significantly for Op in T1. Conclusions. Op was superior to FT in regard to pain, osmolarity, TBUT,
and Schirmer 1. Osmoprotectant solutes, such as L-carnitine, could attenuate inflammation and secondary DED.
Osmoprotective lubricants can be effectively applied for the prevention of refractive surgery-related dry eye symptoms
and signs.
1. Introduction
Dry eye disease (DED) is a complex and multifactorial
disease, which is reported as a complication in 40 to
60% of refractive surgery patients [1–3]. Reduced corneal
sensation was proposed as the basis of reduced blinking
and tear secretion after laser-assisted in situ keratomileu-
sis (LASIK) surgery, and both can contribute to a state of
aqueous deficiency [4]. Additionally, it was proposed that
such symptomatic condition is due to disruption of trophic
sensory input to the denervated region. This was denomi-
nated LASIK-induced neuroepitheliopathy (LINE) [5]. A
similar situation may occur subsequent to photorefractive
keratectomy (PRK) [6]. Postoperative discomfort has
been described as a drawback of PRK, hence requiring
pain and discomfort management with topical NSAIDs,
gabapentin, oxycodone and acetaminophen, diclofenac, or
others [7].
The use of nonpreserved artificial tears and other lubri-
cants has been suggested as useful for the treatment of dry
eye symptoms and for reducing the impact on goblet cell
density after LASIK [8]. The few studies that to date have
investigated tear osmolarity after LASIK have found that
osmolarity drops immediately after surgery and increases
significantly and remains markedly higher for at least 6
months [9–11]. Tear film hyperosmolarity activates MAP
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kinases and NF-κB signalling pathways in ocular surface
epithelial cells [12, 13] and the generation of inflammatory
cytokines [14]. Therefore, the purpose of this study was to
verify the therapeutical effect of an osmoprotective eye drop
(Optive) for the management of induced aqueous deficient
DED in patients subjected to refractive surgery.
2. Patients and Methods
This research protocol was approved according to the Ethics
Committee in Research, UNIFESP, under number 1346/08
and registered at http://ClinicalTrials.gov (ID number
NCT01741987). The visits were established before surgery
(T0) and 1-month (T1) and 3-month (T3) posttreatment
with osmoprotective and nonosmoprotective lubricants.
Twenty-two patients were selected from the Refractive
Surgery Department, UNIFESP, who were referred for
bilateral LASIK (11 patients) or PRK (11 patients). Patient
number was calculated by previous pilot study with pain as
the primary outcome, in which 100% Op patients reported
improvement after 3 months. LASIK flap insertion position
was superior and performed with Moria™ microkeratome.
The flap was 9mm in diameter and 130μm thick. The refrac-
tive surgery applied excimer argon fluoride laser (193 nm)
(LADAR Vision 4000, Alcon). A suspension of topical ste-
roid and antibiotic (moxifloxacin 0.5% and dexamethasone
phosphate 0.1%) was prescribed postoperatively for patients
QID for 1 week (LASIK) and 2 weeks (PRK). Consecutively,
thirteen patients were randomised by an online random
allocation tool to receive topical administration QID of
FreshTears (FT, Allergan Inc.) (6 LASIK and 7 PRK) while
nine patients were given topical administration QID of
Optive (Op, Allergan Inc.) (5 LASIK and 4 PRK). Labels
were removed, and both drops were repackaged in dark
plastic bags in order to mask the brands to patients and
principal investigator.
Optive contains sodium carboxymethylcellulose (CMC),
glycerine, erythritol, and stabilised sodium chlorite complex
(Purite™). The main osmoprotectant component is L-carni-
tine, and its osmolarity is 328mOsm/L [15]. FreshTears
contains CMC, sodium chloride, potassium chloride, cal-
cium chloride dihydrate, magnesium chloride hexahydrate,
boric acid and sodium borate decahydrated (as buffering
agents), purified water, and Purite. The osmolarity of FT
is 280mOsm/L.
The subjects were submitted to the following tests,
exactly in the order cited, during the first visit (T0) and
at follow-up visits (T1 and T3): best spectacle-corrected
visual acuity (BSCVA) converted for LogMar scale, tear
film osmolarity by electrical conductivity [16], biomicro-
scopy [17], Schirmer 1 test without anesthesia [18], tear film
breakup time (TBUT) [18], fluorescein staining [19], com-
pleting patient’s symptoms questionnaire and ocular surface
disease index (OSDI) [20], lissamine green staining [18], and
impression cytology (IC) and staining by periodic acid Schiff-
hematoxylin (PAS-H). Total IC scores were defined as a sum
of scores for each morphological change, such as cellularity,
cohesivity, nuclear/cytoplasm ratio, snake-like chromatin,
goblet cell density, and inflammation [21]. Consecutively,
delta IC total scores were calculated by the difference between
T0 scores and T3 total scores. Reported pain and osmolarity
data were regarded as the primary outcome measures.
Safety parameters were assessed through eye exams and
observation of adverse events throughout the study. If an
adverse event was severe or caused impact to the patients’ life
quality, treatment would be interrupted.
Continuous data distribution was analysed by
Kolmogorov-Smirnov normality test. Values were repre-
sented by sample mean and standard deviation or standard
error of the mean (SEM). Baseline demographical and oph-
thalmological data were analysed by Student’s unpaired t-test
when parametric and Mann-Whitney test when nonpara-
metric. When more than 2 samples and 2 periods were com-
pared, the repeated measures ANOVA with Tukey posttest
was applied. Nonparametric data were represented by infe-
rior and superior quartile median, with Wilcoxon compari-
son when 2 periods were analysed and Friedman when
more than 2 periods were analysed. A p value of less than
0.05 was accepted as statistically significant. GraphPad Prism
version 5 was used for statistical analyses.
3. Results
Baseline demographical and ophthalmological examina-
tion data are summarised in Table 1. There was no statis-
tically significant difference between groups for the evaluated
parameters.
3.1. OSDI and Symptoms Questionnaire. After refractive sur-
gery was performed, patient maintenance started with FT
and Op administration and evaluated at 1- and 3-month
follow-up. A comparison of the mean OSDI scores did not
reveal any changes in the evaluated periods (repeated mea-
sures ANOVA, p > 0 05).
Table 1: Baseline demographical and ophthalmological
examination data of patients randomised into FT and Op
treatments.
FT (n = 13 26) Op (n = 9 18) p value
Age (years) 38.21± 11.52 33.00± 7.75 0.4425
Gender (as female %) 71.4% 54.5% 0.4108
OSDI (score) 14.48± 3.26 24.95± 5.99 0.1176
Schirmer 1 (mm/5min) 21.22± 10.47 25.77± 10.85 0.0961
TBUT (sec) 8.18± 4.02 8.28± 3.89 0.9758
Fluorescein (score) 0.15± 0.36 0.32± 0.68 0.1644
Lissamine (score) 1.04± 0.61 0.82± 0.66 0.2342
BSCVA (LogMar) 0.002± 0.052 0.036± 0.072 0.109
Osmolarity (mOsm/L) 359.5± 9.52 383.3± 8.33 0.0781
Spherical equivalent (D) −4.02 ± 2.8 −3.56 ± 1.7 0.5745
Contact lens users (%) 42.86% 44.44% 0.7219
Contact lens use (years) 9.2 ± 10.2 8.5 ± 4.2 0.6689
Values represent mean ± standard deviation. OSDI: ocular surface disease
index; TBUT: tear film breakup time; BSCVA: best spectacle-corrected
visual acuity.
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In regard to symptoms questionnaire, Op-treated
patients reported more dryness at T1 visit (Friedman test,
p < 0 01), though both treatments showed a return to base-
line values at T3 (Figure 1(a)). The symptom of pain
increased significantly for the FT group between T0 and T3
(Friedman test, p < 0 05) but tended to be lower than baseline
in the Op group for T1 and T3 (Figure 1(b)). However, the
symptoms of burning (ANOVA-Tukey, p > 0 05), foreign
body sensation and blurred vision (Friedman, p > 0 05),
and photophobia and sum of all symptoms (repeated mea-
sures ANOVA, p > 0 05) showed no difference between
treatments for all periods.
3.2. Ophthalmological Exams. Visual acuity, as evaluated
by LogMar scale, did not present any difference between
treatment groups, for the T1 and T3 periods (Wilcoxon,
p > 0 05).
A significant reduction in osmolarity values between T1
and T3 in comparison to T0 for the Op group was observed
(ANOVA-Tukey, p < 0 01), while for the FT group, a differ-
ence was observed only between T0 and T3 (ANOVA-Tukey,
p < 0 05) (Figure 2(a)).
It was noticed that Op significantly improved Schirmer 1
at T1 and returned to baseline values at T3 (Friedman test,
p < 0 01) (Figure 2(b)). Additionally, the analysis of TBUT
showed no statistically significant difference between periods
for both groups (Friedman test, p > 0 05).
Considering vital stains, no alteration was observed
for lissamine green staining (repeated measures ANOVA,
p > 0 05) and fluorescein (Friedman test, p > 0 05).
3.3. Impression Cytology. It was assessed whether FT and
Op groups showed differences between T0 and T3 scores of
ocular surface changes as shown by PAS-H staining in
impression cytology samples. Delta total score analysis
revealed no significant change for superior, temporal, and
both regions grouped (Mann-Whitney, p > 0 05) (Figure 3).
4. Discussion
According to the Dry Eye WorkShop (DEWS) [22], LASIK-
induced dry eye is a form of non-Sjögren’s syndrome (SS)
aqueous deficient DED. After LASIK or PRK, patients can
report significant dry eye for several months, an effect that
is due to the section of corneal nerves during surgery [23].
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Figure 1: Mean and SEM values of questionnaires scores compared between FT and Op groups before surgery (T0) and 1 month (T1)
and 3 months (T3) after treatment. (a) Dryness scores. The score is significantly higher for Op group in T1 compared to T0 (Friedman
test, ∗∗p < 0 01). (b) Pain scores. There was a significant increase between T0 and T3 for the FT group (Friedman test, ∗p < 0 05).
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Figure 2: (a) Tear osmolarity mean and SEM values compared between FT and Op groups before surgery (T0) and 1 month (T1) and 3
months (T3) of treatment. FT group presented a significant reduction in osmolarity values after 3 months of treatment (∗ANOVA-Tukey,
p < 0 05). In the Op group, reduced osmolarity was noted between T0 and T1 and T0 and T3 (∗∗ANOVA-Tukey, p < 0 01). (b) Schirmer 1
test mean and SEM values. An increase was observed for Op group, in T1 only (Friedman test, ∗∗p < 0 01).
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The sensory denervation of the ocular surface after bilateral
LASIK disrupts the lachrymal dynamics and causes irritation
symptoms [24]. Sub-basal nerves begin to recover from 3
to 6 months after surgery and are 50% of the original preop-
erative density within 2 years after surgery [25]. In a rando-
mised trial, symptoms of DED apparently resolved at 1 year
postoperatively, for both LASIK and PRK [6].
In the present study, patients who underwent LASIK
and PRK were grouped, and according to published data,
corneal sensitivity is reduced by both techniques until 3
months postoperatively [26]. Previous studies have shown
that there is no significant difference in dry eye symptoms
between LASIK and PRK without ocular surface manage-
ment. [8]. Also, Toda et al. evaluated the effect of LASIK
in patients with and without dry eye before surgery, and
the recovery time of corneal sensitivity in non-dry eye
patients was 3 months [27]. We did not perform esthesiome-
try tests because of diurnal variability of corneal sensitivity
[28], and approximately 45% of patients were contact lens
users (as shown in Table 1), a condition reported to reduce
corneal sensitivity [24].
Evaluation of dryness showed significantly increased
scores for the Op-treated patients at T1 and decreased at
T3. Though not significant, this pattern was also observed
for FT. This seems to point to the effect of LASIK denervation
(1 month) and improvement conferred by FT and Op
(3 months), possibly related to the viscoelastic properties of
CMC and lubricants. Carboxymethyl cellulose-based eye
drops have been widely used after LASIK to accelerate recov-
ery of the ocular surface and to minimise symptoms [29]. It
has been described that Op treatment was able to diminish
symptoms such as dryness, foreign body, and burning
compared to baseline score values [30]. It is noteworthy,
however, that while pain score worsens significantly for FT
group, Op treatment appears to reduce pain complaints, a
possible anti-inflammatory effect of osmoprotection. To the
authors’ knowledge, this is the first report of a non-anti-
inflammatory drug that can be applied for the management
of postrefractive surgery pain and discomfort. Although with
a relatively small patient number, pain reduction seems to be
consistent and has also been observed in evaporative dry eye
patients as well (unpublished data).
Additionally, refractive surgery increases tear osmolarity,
with no significant difference between LASIK and LASEK
[10]. Refractive surgery severs corneal nerve endings, and
the loss of stimulation increases osmolarity by decreasing lac-
rimal gland secretion of proteins, electrolytes, and water [31].
Posttreatment osmolarity values measured in our study by
electrical conductivity were similar to normal values found
by Ogasawara et al. [16]. Notwithstanding, it should be
remarked that lenses use can cause increased tear film osmo-
larity, with no association with ocular symptoms [32, 33],
which could explain our elevated baseline osmolarity values.
Lee et al. evaluated tear osmolarity post-LASIK and PRK and
have found that it peaked after 3 months and returned to
baseline values in 6 months and suggested dry eye treatment
for these patients [11]. Herein, we observed a significant
reduction in tear osmolarity values for Op group after
1 month postoperatively, which was sustained also after
3 months. However, FT control treatment decreased osmo-
larity only after 3 months, but not after 1 month, as previ-
ously reported by Benelli et al. [34]. Considering that
hyperosmolarity leads to ocular surface inflammation [35],
this earlier osmolarity reduction could be a result of osmo-
protectant compatible solutes present in the composition of
Op, such as L-carnitine [36], and thus, may attenuate inflam-
mation and DED secondary to LASIK and PRK.
Tear secretion (Schirmer 2 with anesthesia) decreases
after LASIK or LASEK and returns to preoperative levels
between 1 and 6 months, when treatment with artificial tears
was led up to two weeks postsurgery [10, 37, 38]. Addition-
ally, without any treatment, Schirmer 1 values decrease 1
week after LASIK, returning to baseline in 3 months [39].
In our study, using Schirmer 1, our results have shown that
while FT patients did not present any significant difference,
Op treatment improved tear secretion at T1, returning to
baseline in T3.
Goblet cell density has been shown to decrease after 1
week and 1 month LASIK [40] and return to preoperative
levels after 6 to 9 months [39], while a reduced nucleus/
cytoplasm ratio can be noticed up to 6 months after surgery.
[40] We did not perform IC at 1 month postoperatively since
it is a short interval to observe therapeutical effects. In our
results, although not statistically significant, an increase of
morphological changes total score by impression cytology
in the temporal region after 3 months, for FT, was observed.
To Op, however, mean scores after refractive surgery did not
change, which could be justified by a possible osmoprotec-
tion effect, leading to less ocular surface damage.
Op has presented superior results than FT in regard to
the parameters of pain, tear film osmolarity, and Schirmer
1, while FT and Op treatments appear to have similar
therapeutic effects on dryness complaints. Eye drops which
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Figure 3: Mean and SEM of impression cytology score deltas
calculated by the difference between 3 months (T3) values and
before surgery (T0) values. No difference was found between FT
and Op treatments (Mann-Whitney, p > 0 05).
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contain osmoprotectant components are interesting phar-
macological resources to safely and effectively prevent
refractive surgery discomfort related to dry eye symptoms
and signs.
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